This page shows results related to Alaway and Blepharospasm from the FDA Adverse Event Reporting System (AERS). The adverse event Blepharospasm has been reported to the FDA a total of 2 times for Alaway.
Learn More About Alaway Adverse EventsThe Proportional Reporting Ratio (PRR) for Alaway and Blepharospasm is 27. The chart below compares this proportional reporting ratio of Blepharospasm for drugs used in similar therapies to Alaway. The higher the proportional reporting ratio is, the more likely a drug is associated with Blepharospasm.
| Blepharospasm | |
| Alaway | 27 |
NOTE: The PRR metric is still in Beta testing by DrugCite and is intended for use by researchers only.
Of those reporting Blepharospasm, why were they taking Alaway?
| Hypersensitivity | 1 |
| Eye Pruritus | 1 |
Which medications reported to the FDA are most commonly associated with Blepharospasm?
| Tysabri | 86 |
| Enbrel | 60 |
| Humira | 39 |
| Strattera | 37 |
| Lupron Depot | 31 |
| Metoclopramide | 30 |
| Abilify | 28 |
| Lamictal | 26 |
| Risperdal | 22 |
| Gilenya | 20 |
| Zyprexa | 20 |
 Show More |
